Who this treatment is actually for

ChondroFiller™ is designed for adults who have significant, full-thickness cartilage damage — graded ICRS or Outerbridge Grade III or IV — but whose joint is otherwise stable and aligned well enough to support the body's own repair process. If that broad profile fits, the injection pathway is worth understanding in more detail.

Two distinct patient groups typically qualify. The first includes people with a focal, contained chondral defect — usually between 1 and 6 cm² — resulting from a sports injury, osteochondritis dissecans (OCD), or damage that followed a meniscal or ligament problem. The second group covers those with more diffuse joint degeneration, broadly classified as Kellgren-Lawrence Grade I to III, where the injectable collagen scaffold coats the articular surface and works with the body's natural cell migration to support cartilage repair.

Age alone does not disqualify a patient. There is no formal upper age limit. Active adults roughly between 40 and 65 who maintain a healthy weight tend to achieve the strongest regenerative response, but younger patients recovering from trauma and older patients managing symptomatic wear are both within the treatment's scope.

The procedure itself is delivered as an ultrasound-guided outpatient injection — no surgery, no general anaesthetic, and no theatre admission. Whether a patient falls into the focal-defect group or the broader OA group, the starting point is the same: a clinical assessment to confirm that the joint environment can support the scaffold's mechanism.

The cartilage damage profile that qualifies

Grading scales like ICRS and Outerbridge describe how deeply cartilage has been lost. Grade III means damage extends beyond half the cartilage thickness but leaves the bone surface intact; Grade IV means the cartilage is gone entirely, exposing the bone beneath. Both grades mark the threshold where a regenerative scaffold has meaningful structural work to do — shallower damage may stabilise without intervention, while bone-on-bone contact across the whole joint typically points toward a different management pathway.

Within that Grade III–IV window, the character of the defect matters. Focal, contained lesions roughly 1–6 cm² sit well within ChondroFiller™'s treatment range, and evidence suggests this size bracket supports stable scaffold borders and reliable progenitor-cell migration. That upper limit is notably broader than microfracture typically accepts, and spans defect sizes where a two-stage cell-cultivation procedure might otherwise be considered.

For patients with more diffuse surface degradation, the scaffold works across a wider articular area rather than filling a single discrete hole, recruiting host progenitor cells along the joint lining. The Kellgren-Lawrence I–III classification corresponds to preserved joint space — a key factor, because the scaffold depends on some remaining healthy cartilage margin as a structural anchor for repair.

Hip presentations carry one further grading consideration. Tönnis grade 0 or 1, indicating minimal to mild radiographic change, is generally within scope; Tönnis grade 2 or 3 suggests degeneration too advanced for the scaffold mechanism to deliver meaningful benefit.

Body weight sits alongside imaging as a practical part of the candidacy conversation. No rigid BMI threshold is specified, but evidence suggests that maintaining a healthy weight reduces joint load during the integration period — which may support a more reliable repair response.

How suitability is assessed before treatment

Most patients arrive at a ChondroFiller™ consultation having already had some imaging, and MRI is exactly where the formal assessment begins. A scan distinguishes a focal contained defect from diffuse surface damage, measures the lesion's geometry, and — critically — flags any features that would redirect care elsewhere before any treatment decision is made.

Functional scoring sits alongside the imaging review. Clinicians typically use a Visual Analogue Scale (VAS) to gauge pain severity and the WOMAC index to measure joint function. These aren't box-ticking exercises: published series suggest that patients with moderate pain and preserved joint space show the most consistent improvement, so the scores help determine whether the scaffold is likely to make a meaningful practical difference for a given patient.

Joint alignment and stability are also reviewed at this stage. Malalignment greater than 5° or significant instability creates uneven mechanical forces that would work against a healing scaffold — either factor would need to be addressed concurrently or beforehand, otherwise it becomes a disqualifying condition. This is assessed clinically and cross-referenced against imaging rather than assumed from the history alone.

The entire process takes place in an outpatient setting — a clinical consultation combining imaging review and functional scoring, with no surgical work-up required.

Why the joint environment matters more than defect size

The reason candidacy screening focuses so intently on the joint's biological environment — rather than defect geometry — comes down to mechanism. Once injected, the collagen scaffold carries no cells of its own: it forms a matrix that draws the body's progenitor cells in from surrounding tissue. If local or systemic conditions are hostile to that migration, no degree of careful sizing or precise placement can compensate.

The most immediate absolute contraindication is hypersensitivity to murine-derived proteins or Type I collagen. Because the scaffold is composed of murine-derived Type I collagen, a known allergy makes the injection itself an allergenic risk and closes the pathway entirely.

Active infection — whether localised to the target joint or systemic — is equally prohibitive. Introducing a biologic scaffold into an infected environment carries unacceptable risk and defeats any prospect of controlled tissue repair.

Inflammatory joint disease, including rheumatoid arthritis and other autoimmune arthropathies, floods the joint with catabolic mediators that work directly against the regenerative process. Metabolic crystal arthropathies — gout and calcium pyrophosphate deposition disease (CPPD) — create the same hostile environment, even during apparently quiescent intervals. Active malignancy and significant bleeding disorders are further safety contraindications where the risk profile for any injectable implant is unfavourable.

Advanced pan-articular osteoarthritis, where degradation is widespread and no healthy cartilage margin remains as an anchor for repair, is a firm exclusion. Patients in this category may be better served by alternatives such as a polyacrylamide hydrogel, viscosupplementation, or, where clinically indicated, joint replacement — each representing a different mechanism and a different role in joint management.

Significant uncorrected malalignment or joint instability, as noted during the assessment stage, also disqualifies without concurrent correction.

How ChondroFiller™ compares to other cartilage options

The defect-size question often prompts patients to ask how ChondroFiller™ sits alongside the other options they may have encountered or been offered.

Microfracture — a surgical technique that penetrates subchondral bone to stimulate clot-based repair — is generally limited to defects smaller than roughly 2–4 cm². As an outpatient injectable scaffold, ChondroFiller™ handles a broader defect-size range without requiring theatre admission. Where defects are larger, the conventional surgical alternative is MACI (Matrix-Induced Autologous Chondrocyte Implantation): a two-stage process involving cell harvesting, laboratory culture, and a second procedure to implant the expanded cells. ChondroFiller™ offers a single-stage injectable route for patients who qualify, bypassing that extended pathway entirely.

The comparison with polyacrylamide hydrogel (Arthrosamid®) is one of mechanism rather than rank. Arthrosamid is a non-regenerative hydrogel that may modify pain through integration into synovial tissue; it does not aim to repair the cartilage structure itself. ChondroFiller™'s collagen scaffold, by contrast, recruits the body's own progenitor cells with the aim of supporting tissue-level repair. The two serve different clinical roles, and which is more appropriate depends on the individual joint profile.

Hyaluronic acid viscosupplementation and corticosteroid injections remain legitimate palliative options — useful for symptom management and acute inflammation — but neither addresses the underlying structural deficit. PRP, microfragmented adipose tissue (mFAT), and bone marrow aspirate concentrate (BMAC) may provide biologic support and are sometimes considered in combination pathways where clinically appropriate; they are not structural scaffold replacements.

What to do if you think you might be suitable

For patients who recognise their situation in the profiles described above, the natural next step is a formal suitability assessment rather than a self-diagnosis. Published series indicate meaningful functional improvement in qualifying patients over twelve months, but individual outcomes depend on defect type, background joint health, and how well activity is managed during the scaffold integration period. The treatment is not appropriate for everyone, and the assessment exists precisely to confirm candidacy before any injection is planned.

Arriving well prepared makes that process more efficient. Bringing any recent MRI — ideally taken within the past twelve to eighteen months — allows imaging to be reviewed against the clinical picture immediately. A clear account of how long symptoms have been present, what activities aggravate them, and which previous treatments have been tried (physiotherapy, injections, surgical procedures) gives the assessing clinician the context needed to determine whether ChondroFiller™ is the right pathway or whether an alternative would serve better.

To find out whether you may be suitable, a suitability assessment is available at amsk.co.uk. Individual candidacy is confirmed only after imaging review and clinical discussion — not before.